From the launch of a new anterior eye inspection device to new collaborations to tackle global blindness and macular degeneration, these are our key eye care stories of the week.
The story behind Lumio. Aston Vision Sciences’s compact anterior eye inspection tool, Lumio comes with a clip-in fluorescein filter, “which allows you to perform a fluorescein examination in a variety of settings without the need for a slit lamp.” “Our ‘trade secret’ is that we’ve developed the color formula for the fluorescein filter to give a very good performance,” Aston Vision Sciences founder Karl Obszanski tells The New Optometrist. “Even in the low blue-light conditions, you can see what’s going on in the eye very clearly.” Obszanski tells us more about the device.
Specsavers joins IAPB to advocate for better eye health. Specsavers has joined the International Agency for the Prevention of Blindness (IAPB) in the global fight against avoidable sight loss. Specsavers’ co-founder, Dame Mary Perkins, explained: “We believe everyone, regardless of their circumstances, deserves access to quality eye health services. That’s why we’ve invested heavily in initiatives like optical coherence tomography (OCT) scans, allowing for early detection of conditions such as diabetic retinopathy and glaucoma – directly aligning with IAPB’s mission to eliminate preventable blindness.” Link
London clinic to offer AI-powered retinal cardiovascular screening. Hodd Barnes Dickins, Holborn, is expanding its eye exams into “a gateway for cardiovascular health” with the Dr.Noon CVD – an AI-powered technology that assesses potential cardiovascular disease (CVD) risk. Dr.Noon CVD analyzes retinal vessel images and identifies key indicators linked to cardiovascular health. Link
SpaMedica teams with the Macular Society. SpaMedica has announced a partnership with the Macular Society to help “fund ground-breaking research and vital support services for patients who have been diagnosed with macular disease, including conditions such as age-related macular degeneration (AMD), currently the leading cause of sight loss in the UK.” Link
By opting-in, you agree to receive email communications from The New Optometrist. You will stay up-to-date with optometry content, news, events and sponsors information.
You can view our privacy policy here
By opting-in, you agree to receive email communications from The New Optometrist. You will stay up-to-date with optometry content, news, events and sponsors information.
You can view our privacy policy here
By opting-in, you agree to receive email communications from The New Optometrist. You will stay up-to-date with optometry content, news, events and sponsors information.
You can view our privacy policy here